Juncell Therapeutics

Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026

Shanghai Juncell Therapeutics Co., Ltd. announced it has published its prospectus and filed for listing...

Company Deals

Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors

Fineline Cube Dec 11, 2025

Shanghai Juncell Therapeutics Co., Ltd. (“JunCell Biologics”) released its prospectus, announcing its intention to list...

Company Drug

Shanghai Juncell Therapeutics’ GC101 TIL Therapy Receives CDE Approval for Pivotal Phase II Trial

Fineline Cube Dec 7, 2024

Shanghai Juncell Therapeutics has announced that the National Medical Products Administration’s Center for Drug Evaluation...

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Company Drug

Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications

Company Drug

AbbVie’s SKYRIZI (Risankizumab) Secures European Commission Approval for Pediatric Plaque Psoriasis – First IL-23 Inhibitor Authorized for Children as Young as Six

Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders